Immune Investigational

Thymosin Alpha-1

An immune-oriented peptide discussed for immunomodulatory signaling and clinical research in infectious disease and oncology-adjacent contexts.

ImmuneImmunomodulationThymic Peptide

Also referenced as: Tα1, Thymalfasin

Price compare
84 tracked offers across 84 vendors · 14 dosages
Best trust-adjusted value: Peptide Supply Co · Strong trust · $3.24/mg
From
$3.24/mg
Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Category
Immune

This profile is grouped by its dominant research and market lane, not by vendor shelf placement.

Aliases
2

Tα1, Thymalfasin

Signal depth
Medium

No FDA label signal · 78 trials · 1325 PubMed results

Promising
Research evidence

Thymosin Alpha-1 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Thymosin Alpha-1 has 24 name-matched clinical trials (highest phase: Phase 4) and 1146 PubMed-indexed publications and is not FDA-approved. 2 trials have posted results.

Human data
Phase 3
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
High-impact
PHASE4 · Randomized Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis PHASE4 · Randomized Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection PHASE4 · Randomized Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients The Journal of Immunology · 238 citations Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. Proceedings of the National Academy of Sciences · 181 citations Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Applied Physics Letters · 172 citations Low-loss single-mode optical waveguides and efficient high-speed modulators of LiNb<i>x</i>Ta1−<i>x</i>O3 on LiTaO3
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What thymosin alpha-1 is

Thymosin alpha-1 is an immune-oriented peptide associated with T-cell and immunomodulatory signaling. It stands apart from many retail peptide names because it has a longer clinical-research history than a typical gray-market recovery compound.

Why it matters

It gives the peptide library a credible anchor for the immune category and helps show that not every non-FDA-approved peptide sits in the same bucket of evidence or seriousness.

Regulatory context

Thymosin alpha-1 is not an FDA-approved peptide drug indication in the United States, but it has been investigated in more formal clinical contexts than many research-market peptides.

Practical reading note

This is exactly the kind of profile where “not FDA approved” should not be confused with “fringe.” The important distinction is between investigational clinical use and generic research-market marketing.